National Institutes of Health (NIH) To Sponsor Clinical Trial For Emergent BioSolutions' Group B Streptococcus Vaccine Candidate

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed a clinical trial agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under which NIAID will fund, manage and conduct a clinical study on EBS-C12, as well as EBS-C12 in combination with EBS-A42. Both EBS-C12 and EBS-A42 are novel recombinant proteins that have been selected for use in the company’s group B streptococcus (GBS) vaccine candidate. This proposed clinical study follows promising results from a first quarter 2006 open-label, dose escalating Phase I clinical trial in the United Kingdom of EBS-A42 in which the protein elicited a statistically significant immune response at all dose levels and was well tolerated by participants with no subjects withdrawing due to an adverse event.

Back to news